Dr Reddys Laboratories (RDY) Operating Margin (2009 - 2026)
Dr Reddys Laboratories (RDY) posted Operating Margin of 4.69% for Q2 2026, up 165.97% on a QoQ basis from 1.76% in Q1 2026, and down 1576.0% year-over-year from 0.32% in Q2 2025.
Analysis
Dr Reddys Laboratories (RDY) Operating Margin (2009 - 2026) Analysis & Trends
Dr Reddys Laboratories has reported Operating Margin for 18 years, with the latest figure at 4.69% in Q2 2026.
- On a quarterly basis, Operating Margin fell 1576.0% year-over-year to 4.69% in Q2 2026; TTM through Jun 2026 was 11.33%, a 1004.0% decrease from a year earlier, with the FY2026 full-year figure at 15.06%, down 681.0% from the prior year.
- Operating Margin was 4.69% for Q2 2026 at Dr Reddys Laboratories, up from 1.76% in the prior quarter.
- The five-year high for Operating Margin was 26.14% in Q1 2023, with the low at 1.76% in Q1 2026.
- Average Operating Margin over 5 years is 19.16%, with a median of 21.51% recorded in 2024.
- The sharpest annual moves came in 2023 and 2026: Operating Margin jumped 2335 bps in 2023, then sank 1898 bps in 2026.
- Over 5 years, Operating Margin stood at 19.69% in 2022, then rose by 22 bps to 23.93% in 2023, then slipped by 6 bps to 22.4% in 2024, then dropped by 27 bps to 16.32% in 2025, then plunged by 71 bps to 4.69% in 2026.
- The last three Operating Margin figures came in at 4.69% (Q2 2026), 1.76% (Q1 2026), and 16.32% (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.53 Bn | 38.88 Bn | 2.15 Bn | -5.58% |
| 2 | Viatris | 19.14 Bn | 18.25 Bn | 1.46 Bn | 0.17% |
| 3 | Dr Reddys Laboratories | 9.86 Bn | 9.69 Bn | 396.53 Mn | 4.69% |
| 4 | Amneal Pharmaceuticals | 5.45 Bn | 5.33 Bn | 334.51 Mn | 16.30% |
| 5 | Bausch Health Companies | 2.33 Bn | 492.63 Mn | 2.10 Bn | 25.95% |
| 6 | Alvotech | 1.51 Bn | 1.36 Bn | 2.56 Mn | -134.08% |
| 7 | Ani Pharmaceuticals | 1.48 Bn | 1.12 Bn | 165.89 Mn | 15.21% |
| 8 | Amphastar Pharmaceuticals | 992.90 Mn | 702.78 Mn | 93.47 Mn | 21.60% |
| 9 | Fennec Pharmaceuticals | 400.20 Mn | 358.95 Mn | 17.15 Mn | 9.72% |
| 10 | RedHill Biopharma | 178.79 Mn | 178.79 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4.69% |
| Mar 31, 2026 | 1.76% |
| Dec 31, 2025 | 16.32% |
| Sep 30, 2025 | 19.89% |
| Jun 30, 2025 | 20.45% |
| Mar 31, 2025 | 20.75% |
| Dec 31, 2024 | 22.40% |
| Sep 30, 2024 | 21.89% |
| Jun 30, 2024 | 23.36% |
| Mar 31, 2024 | 21.12% |
| Dec 31, 2023 | 23.93% |
| Sep 30, 2023 | 25.97% |
| Jun 30, 2023 | 25.97% |
| Mar 31, 2023 | 26.14% |
| Dec 31, 2022 | 19.69% |
| Sep 30, 2022 | 24.27% |
| Jun 30, 2022 | 23.42% |
| Mar 31, 2022 | 2.79% |
| Dec 31, 2021 | 10.46% |
| Sep 30, 2021 | 17.40% |